4SCAR-T therapy for B-cell cancer after CD19 treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of CAR T-cell therapy (4SCAR-T) for people whose B-cell cancer has returned after a prior CD19-targeted treatment. The therapy targets several other proteins on cancer cells to try to stop the cancer again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 6 months.
- Your B-cell cancer came back after you had a treatment that targets CD19 (like CAR T-cell therapy).
- Your cancer cells have at least one of these proteins: CD22, CD123, CD38, CD10, or CD20.
- You are healthy enough to care for yourself (score 80 or higher on a standard scale) and likely to live at least 1 more month.
- Your hemoglobin level is above 80 g/L (a measure of red blood cells).
- You do not have uncontrolled infections, HIV, active hepatitis B or C, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
This trial tests a new type of CAR-T cell therapy that targets multiple markers on B-cell lymphoma cells. It is for patients whose lymphoma has certain surface markers and who are in reasonably good health.
This trial tests a lab-made immune treatment (CAR-T cells) designed to attack cancer cells that carry CD19 or CD22. It may help people whose B-cell cancers have those markers, provided they meet safety and health requirements.
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
This early-phase trial tests a customized immune cell therapy (CAR-T) that targets cancer cells with CD19 or CD70 markers on their surface. It may help your body fight the cancer by directing new immune cells to recognize and attack those cells.
This trial studies a type of immune treatment (CAR-T cells) designed to calm overactive immune disease. It may help by aiming the therapy at immune cells involved in B-cell activity, but it has strict health and safety requirements.
Hear when a new CD19 Negative B-cell Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.